GlaxoSmithKline has announced new results from a clinical trial showing that Pandemrix elicited a strong immune result in children and adolescents aged between 3 and 17 years of age.

The new trial data establishes the effectiveness as well as the safety of the vaccine, of which 40 million doses have already been delivered worldwide, for all ages from infants to the elderly.

GSK Biologicals president Jean Stéphenne said that these results complete GSK’s initial post first dose data across all age ranges.

“We are making this information available in as short a time as possible. This allows authorities to have a more complete understanding of how the vaccine can be used in all age groups,” Stéphenne said.

The trial, which is ongoing, exceeded recommended immunogenicity criteria in three children cohorts tested, 100% of which demonstrated responses above the regulatory threshold of 1:40 seroprotection, which is considered indicative of protection in adults.